Two candidates and their preclinical results
- CKLS118: a circular RNA-based vaccine that, combined with PD-1 inhibitors, slowed tumour growth by up to 88.9 per cent, compared with up to 68.6 per cent with PD-1 inhibitors alone.
- CKLS202: designed to target the cancer marker Prame while blocking the PD-1 receptor, it inhibited tumour growth by 65 per cent in a preclinical trial.
Melvin Toh, vice-president and chief scientific officer of CK Life Sciences, said the results would support the advancement of both candidates towards human clinical trials.
Encouraging results.
– Melvin Toh
The advantage of circular RNA
In August, Sequencio said its circular RNA-based approach aimed to deliver “off-the-shelf, non-personalised” treatments. That could make therapy more accessible than personalised mRNA vaccines, which require custom manufacturing tailored to each patient's tumour.
















